Effects of Patient Portal Message Framing on Treatment Preferences and Expectations for Degenerative Meniscus Tears: Randomized Exploratory Cross-Sectional Survey Study

<strong>Background:</strong> Degenerative meniscus tears are common in middle-aged and older adults, and current guidelines favor nonoperative care. As patients increasingly turn to portal systems to view imaging results and communicate with their physicians, patient-facing wording may shape downstream treatment preferences and expectations. <strong>Objective:</strong> This study aimed to determine whether subtle differences in physician message framing about an identical degenerative meniscus tear influence preferred management, expectations for improvement with conservative therapy, and satisfaction when a physician recommends a different plan. <strong>Methods:</strong> A cross-sectional 37-question survey was developed de novo and distributed in January 2026 to lay adults in the United States (≥18 years) recruited via Amazon Mechanical Turk. Respondents were presented with a standardized vignette of an adult aged 60 years with knee pain due to a degenerative meniscus tear. Participants were randomized in a 1:1:1 fashion into 3 physician portal message framing groups: neutral, degenerative, and damage. Outcomes were the preferred next step in treatment, expected improvement with physical therapy, and retained satisfaction under physician-respondent disagreement. Chi-square and Fisher exact tests were used to compare categorical variables. Multivariable logistic regression analyses were used to assess associations between framing groups. <strong>Results:</strong> Of the 266 completed responses, 195 (73.3%) were included for analysis (neutral: n=67, 34.4%; degenerative: n=63, 32.3%; damage: n=65, 33.3%). Treatment preferences differed significantly across groups (<i>χ</i><sup>2</sup><sub>2</sub>=6.1; <i>P</i>=.047), and the damage group was significantly more likely to prefer aggressive interventions (odds ratio 2.43, 95% CI 1.17-5.06; <i>P</i>=.02). Expectations for physical therapy success differed significantly (<i>χ</i><sup>2</sup><sub>4</sub>=12.3; <i>P</i>=.02), with the damage group being most pessimistic about conservative care. Retained satisfaction under physician-respondent disagreement did not differ by framing group (<i>χ</i><sup>2</sup><sub>6</sub>=6.7; <i>P</i>=.35) but did differ significantly by initial treatment preference (<i>P</i>=.03) and was the lowest among respondents preferring steroid injection. <strong>Conclusions:</strong> In this exploratory investigation, subtle differences in physician portal message framing regarding a magnetic resonance imaging impression of a degenerative meniscus tear were associated with shifts in treatment preferences and confidence in conservative care. These findings suggest that brief physician portal communications may be associated with shifts in hypothetical patient expectations and treatment preferences before clinical counseling occurs. <strong>Trial Registration:</strong>

STAT+: STAT examines America’s deadliest drug

“Under-babied.” Dr. Oz said that’s the name for a condition that affects one-in-three Americans. I guess that means over-babied is the condition of having too many kids, but then what do you call having the right number of babies? Baby-neutral? Balanced-babied? Send news tips and your favorite lines from Raising Arizona to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.

Scrambling for work requirement exemptions

Patient groups are jockeying for exemptions from Medicaid work requirements, but the unusually fast implementation timeline for states is causing headaches.

Advocates for people in Medicaid would prefer that the federal government exempt specific patient populations from new requirements that able-bodied adult Medicaid beneficiaries work at least 20 hours a week, or be in school or volunteer for community service. Otherwise, it’ll be difficult to help people navigate a state-by-state patchwork of rules.

Continue to STAT+ to read the full story…

<![CDATA[Anti-inflammatory drugs ease anhedonia and depressive symptoms in high-CRP depression, spotlighting CRP-guided treatment and lifestyle strategies while calling for stronger RCTs.]]>

STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more

Top of the morning to you, and a fine one it is. Sunny skies and mild breezes are enveloping the Pharmalot campus once again. Who could ask for anything more? Actually, we could. Specifically, we would like another cup of stimulation. So off we go to the Pharmalot cafeteria to fire up the coffee kettle. Our choice today is maple cinnamon French toast. Please feel free to join us. Meanwhile, we have assembled a few items of interest for you to peruse. We hope you have a smashing day and conquer the world. And of course, do stay in touch. …

The 17 pharmaceutical companies anchoring TrumpRx, the White House’s new prescription drug-pricing program, poured more than $130 million into federal lobbying in 2025 — a nearly 23% surge that outpaced the broader industry as the plan was being shaped behind the scenes, according to OpenSecrets, the nonprofit that tracks campaign financing and lobbying. Those companies accounted for more than a quarter of the record $457.3 million spent on lobbying last year across the pharmaceutical and health products industry. And while newly filed 2026 first-quarter reports show no slowdown — industry-wide spending topped $131 million, a 5.7% year-over-year increase — the most consequential lobbying push came in 2025, ahead of TrumpRx’s February launch.

Eli Lilly paused its obesity awareness campaign in India after the nation’s drugs regulator warned the company it could violate rules against advertising prescription ​medicines to consumers even indirectly, Reuters reports. The campaign titled “We Know Now” was launched in mid-2025, ‌shortly after Lilly introduced its Mounjaro diabetes and obesity treatment in India. Its message focused on reframing obesity as a chronic disease rather than a personal failing. The campaign featured newspaper ads, social media posts, billboards, collaborations with Bollywood celebrities, and posters in a few residential communities. Lilly’s corporate logo appeared on the messages, but Mounjaro was not mentioned. In a 16-page letter dated April ​10 and sent to the Drugs Controller General of India, Lilly said it had halted the campaign “out of an abundance of regulatory caution” following a March ​advisory from the regulator.

Continue to STAT+ to read the full story…

<![CDATA[How FDA priority review vouchers speed psychedelic therapy approvals.]]>

The Download: a Nobel winner on AI, and the case for fixing everything

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.

Three things in AI to watch, according to a Nobel-winning economist

A few months before he won the Nobel Prize in economics in 2024, Daron Acemoglu published a paper that earned him few fans in Silicon Valley. He argued that AI would give only a small boost to US productivity and would not eliminate the need for human work.

Two years later, Acemoglu’s measured take has not caught on. The technology has advanced quite a bit since his cautious predictions, but the data is still largely on his side. 

MIT Technology Review spoke with him to understand if any of the latest developments have changed his thesis. Here are the three things Acemoglu is paying closest attention to in AI right now.

—James O’Donnell

This story is from The Algorithm, our weekly newsletter giving you the inside track on all things AI. Sign up to receive it in your inbox every Monday. 

The case for fixing everything

Stewart Brand, the counterculture icon and tech industry legend, considers maintenance a “civilizational” act. His new book argues that taking responsibility for maintaining something, whether a motorcycle, a monument, or the planet, can be radical.

Brand argues that maintainers haven’t gotten the laurels they deserve—and he’s right. Yet his vision of maintenance often feels solitary: profound, but more about personal fulfillment than tending to a shared world or making it better.

Read the full review of his handsome new book, Maintenance: Of Everything, Part One.

—Lee Vinsel

Lee Vinsel is an associate professor of science, technology, and society at Virginia Tech, a cofounder of The Maintainers, and the host of Peoples & Things, a podcast about human life with technology.

This story is from the latest edition of our print magazine, which is all about nature. Subscribe now to read the full issue and receive future print copies once they land.

The must-reads

I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.

1 The first zero-day exploit built by AI has been discovered
Google spotted and stopped the attempted “mass exploitation event.” (CNBC)
+ The hackers used AI to discover an unknown bug. (NYT $)
+ AI-powered hacking has exploded into an industrial-scale threat. (Guardian)
+ New tools are simplifying online crime. (MIT Technology Review)

2 OpenAI just launched its answer to Claude Mythos
Daybreak patches vulnerabilities before attackers find them. (The Verge)
+ Sam Altman said it will “continuously secure software.” (Gizmodo)
+ It will rival Anthropic’s Claude Mythos, which arrived a month ago. (BBC)
+ OpenAI is allowing wider access to its cyber models than Anthropic. (CNBC)

3 Trump is heading to China to spread the gospel of American tech
While taking cues from Beijing’s more stringent approach. (Guardian)
+ But investors want Trump and Xi to stay out of AI’s way. (Reuters $)
+ Elon Musk and Tim Cook are joining him on the trip this week. (BBC)

4 Ilya Sutskever has testified on Sam Altman’s “pattern of lying”
OpenAI co-founder Sutskever took the stand in the Altman v. Musk trial. (BI)
+ He said he spent a year gathering proof of Altman’s dishonesty. (Reuters $)
+ But he also added to OpenAI’s defense. (Wired $)
+ While Satya Nadella called attempts to remove Altman “amateur city.” (FT $)
+ Here’s what happened last week in the trial. (MIT Technology Review)

5 A new hantavirus vaccine is in the works
Moderna and Korea University are developing an mRNA vaccine. (Wired $)
+ Here’s what you need to know about the cruise ship outbreak. (MIT Technology Review)

6 Texas has sued Netflix over alleged data harvesting and “addictive” design
AG Ken Paxton accuses Netflix of secretly collecting and selling user data. (Quartz)
+ And spying on children while deliberately fostering addiction. (Guardian)

7 A data center guzzled 30 million gallons of water—and no one noticed
The curious case serves as a warning for other data center projects. (Ars Technica)

8 Europe is reportedly selling spyware to human rights abusers
EU states allegedly sold the tech to countries violating rights. (Bloomberg $)

9 The US government’s AI vetting announcement has mysteriously vanished
It had detailed a security test agreement with Google, xAI, and Microsoft. (Gizmodo)

10 Amazon staff are using AI for pointless tasks just to inflate usage scores
In a bid to impress managers. (FT $)
+ An AI expert says we should stop using AI so much. (MIT Technology Review)


Quote of the day

“This is like the cheating husband complaining about the cheating wife.” 

—Anupam Chander, a professor of law and technology at Georgetown Law School, tells the New York Times that Elon Musk’s hypocrisy over OpenAI becoming a for-profit company will undermine his courtroom battle with Sam Altman.

One More Thing

""

STUART BRADFORD


How sounds can turn us on to the wonders of the universe

For decades, astronomy has relied on visual information to make sense of the cosmos: images, charts, and graphs. Now, some researchers are trying something different: listening to the universe.

Using sonification, the process of turning information into sound, they’re helping blind and visually impaired researchers explore the cosmos—and even uncover patterns that might otherwise go unnoticed. The approach is spreading beyond astronomy into fields like climate science, navigation, and education.

Discover how sound could make science more accessible—and even more revealing.

—Corey S. Powell

We can still have nice things

A place for comfort, fun, and distraction to brighten up your day. (Got any ideas? Drop me a line.)

+ This musical mashup beautifully blends LCD Soundsystem with Twin Peaks.
+ Match your speculative ideas to sci-fi stories with the Extrapolated Futures Archive.
+ A live-action animation Coyote vs. ACME is coming soon—and the first trailer just dropped.
+ Want to surf elsewhere in the galaxy? Here’s what it would be like to catch waves on distant planets.